Human Microbiome Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028, Segmented By, Product (Prebiotics, Probiotics, Medical Food, Supplements, Others), By Application (Therapeutic, Diagnostic), By Disease (Infectious Disease, Endocrine and Metabolic Disorders, Gastrointestinal Diseases, Cancer, and Other Disease), By Technology (Genomics, Proteomics, Me
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationHuman Microbiome Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028, Segmented By, Product (Prebiotics, Probiotics, Medical Food, Supplements, Others), By Application (Therapeutic, Diagnostic), By Disease (Infectious Disease, Endocrine and Metabolic Disorders, Gastrointestinal Diseases, Cancer, and Other Disease), By Technology (Genomics, Proteomics, Me
Global human microbiome market is anticipated to observe an impressive growth during the forecast period, 2024-2028. The market growth can be attributed to ongoing increasing demand for the development of human microbiome therapy. The human microbiome therapy is actively associated with the drug development procedures, the surge in demand for advanced medicines is driving the growth of the global human microbiome therapy market in the forecast period. Moreover, increasing instances of lifestyle diseases is driving the market growth in the upcoming future.
Increased Application in Cancer Treatment
According to Clinicaltrials.gov, 5213 clinical trials are in different phases of development across the globe for Colorectal Cancer
Growing Human Awareness for Better health
Autoimmune diseases such as diabetes, rheumatoid, arthritis, muscular dystrophy, multiple sclerosis, and fibromyalgia are associated with dysfunction in the microbiome. Since the bacteria in the microbiome helps digest our food, protect against other disease-causing bacteria, regulate our immune system, produce vitamin B12, thiamine, riboflavin, and Vitamin K essential for blood coagulation. Moreover, the response to the intake of probiotics and prebiotics observed among the healthy adults supports the existence of potential gut microbiota thus increasing the acceptability for human microbiota among the population and thereby supporting the market. Increasing Also, growing awareness regarding the relation of nutrition, diet, and health is expected to support the market growth in the coming future. Furthermore rising awareness about the human microbiome is creating a huge opportunity for the patient suffering Gastrointestinal (GI) illness such as Gut dysbiosis and is therefore creating treatment opportunities such as fecal transplants ,etc. The fecal transplant includes the transfer healthy gut microbiota from an individual to the gastrointestinal tract of a patient suffering gut dysbiosis. Therefore targeting gut microbiota with frequent clinical interventions has now been as a novel approach for disease treatments and is thus human microbiome is in in huge demand expected to treat and even reverse illness including gut health.
Growing Focus on Human Microbiome Therapeutics Development
The National Center for Complementary and Integrative Health (NCCIH) is among the many agencies funding research on the microbiome. Additionally, the National Institutes of Health (NIH) has spent USD 215 million on the Human Microbiome Project (HMP) along with the USD 728 million spent on extramural human microbiome research initiatives outside of HMP over a ten-year period
Growing Incidence of Lifestyle Diseases
. According to WHO, non-communicable diseases or NCDs, of which lifestyle diseases are a part, is over 70% of all deaths across the globe. Incidence of non-communicable disease such as inflammatory bowel disease, inflammatory chronic disease and allergies has become an important health issue worldwide.
The changing dietary habits worldwide i.e., consumption of more processed and unhealthy foods, unhealthy lifestyle habits such as smoking, alcohol, drug consumption leads to gut dysbiosis and other inflammatory gut health issues, which in turn is creating more demand for the human microbiome market and thereby is anticipated to support the market in the future.
Download Free Sample Report
The Global Human Microbiome Market is segmented by product, application, diseases, technology, Type, competitional landscape, and regional distribution. Based on product, the market is further segmented into prebiotics, probiotics, medical food, supplements, and others. Based on the application, the market is further fragmented into therapeutic and diagnostic. Depending on the Disease, the market is segmented into Infectious Disease, Endocrine and Metabolic Disorders, Gastrointestinal Diseases, Cancer, and Other Disease. Based on the Technology, the market is further grouped into Genomics, Proteomics and Metabolomics. Depending on the Type, the market is grouped into FMT, Peptide, Live Biotherapeutic Product and Others.
In 2018, Rebiotrix joined with Ferring pharmaceuticals-a globally recognized specialty pharmaceutical company to lead their ability to make microbiota-based live biotherapeutics more efficiently and supply worldwide.
In November 2022, Ferring pharmaceuticals announced its product REBYOTA- a first class microbiota -based live biotherapeutic for the prevention of recurrence of Clostridioides difficile infection (CDI) among the individuals for 18 and above age . The REBYOTA safety is considered a largest clinical trial program in the field of microbiome-based therapeutics,and is now a US Food and FDA approved microbiota based live biotherapeutic.
Enterome Bioscience SA, Yakult Honsha Co. Ltd., Dupont Inc., Seres Therapeutics Inc., Synthetic Biologics Inc., Second Genome Inc., uBiome Inc., Rebiotix Inc., Microbiome Therapeutics LLC, Osel Inc., Merck and Co., Inc., AOBiome LLC, Vithera Pharmaceuticals Inc., AG Metabiomics Corporation, Ferring Pharmaceuticals SA, are some of the key players operating in the Global Human Microbiome Market.
| Attribute | Details |
| Base Year | 2022 |
| Historical Years | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | · Product · Application · Disease · Technology · Type |
| Regional Scope | North America; Asia Pacific; Europe & CIS; South America; Middle East & Africa |
| Country Scope | United States; Canada; Mexico; China; India; Japan; South Korea; Australia; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; Saudi Arabia; UAE; South Africa |
| Key Companies Profiled | Enterome Bioscience SA, Yakult Honsha Co. Ltd., Dupont Inc., Seres Therapeutics Inc., Synthetic Biologics Inc., Second Genome Inc., uBiome Inc., Rebiotix Inc., Microbiome Therapeutics LLC, Osel Inc., Merck and Co., Inc., AOBiome LLC, Vithera Pharmaceuticals Inc., AG Metabiomics Corporation, Ferring Pharmaceuticals SA. |
| Customization Scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy